Literature DB >> 9640369

The characteristics of urticaria in 390 patients.

F Humphreys1, J A Hunter.   

Abstract

Data were collected on 390 patients who attended a dermatology out-patient department in whom a clinical diagnosis of urticaria was made. Two hundred and thirty-seven (61%) were women. The median age at onset of symptoms was 40 years. Sixty-one (16%) had acute urticaria with symptoms of less than 6 weeks duration at presentation. The disorder was deemed idiopathic in 217 (56%) patients, 59 (15%) had physical urticaria and 57 (15%) had both idiopathic and physical urticaria. Thirty-eight (10%) patients reported intolerance to salicylate or similar drugs, and 31 of these 38 patients also had idiopathic symptoms. One hundred and seventy-two (44%) patients reported a good response to treatment with H1 receptor antagonists. Those who gained little or no benefit from these drugs were more likely to have a physical urticaria (P < 0.05) or to report intolerance reactions (P < 0.05). Only 113 (29%) patients were asymptomatic when discharged. One in five of a small sample contacted still had symptoms 10 years after presentation. Patients seen in an urticaria clinic were less likely to have routine investigations performed and more likely to be discharged at first attendance. When compared with previous published surveys, these figures show a lower proportion of intolerance reactions and a greater proportion of patients responding well to treatment with antihistamines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9640369     DOI: 10.1046/j.1365-2133.1998.02175.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

1.  [Physical urticaria].

Authors:  M Fleischer; J Grabbe
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

2.  Dissociation between history and challenge in patients with physical urticaria.

Authors:  Hirsh D Komarow; Sarah Arceo; Michael Young; Celeste Nelson; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2014-09-08

3.  [Chronic urticaria. Prevalence, course, prognostic factors and impact].

Authors:  K Weller; S Altrichter; E Ardelean; K Krause; M Magerl; M Metz; F Siebenhaar; M Maurer
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

Review 4.  Chronic urticaria: aetiology, management and current and future treatment options.

Authors:  Martina M A Kozel; Ruth A Sabroe
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Non-interventional study comparing treatment satisfaction in patients treated with antihistamines.

Authors:  Christine De Vos; Krassimir Mitchev; Marie-Etienne Pinelli; Marie-Paule Derde; Rossen Boev
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 6.  An approach to the patient with urticaria.

Authors:  S J Deacock
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

7.  Chronic urticaria and treatment options.

Authors:  Kiran Vasant Godse
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

Review 8.  The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; R Maximiliano Gomez; Sandra González-Diaz; Bryan Martin; Mário Morais de Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-03       Impact factor: 4.084

Review 9.  Study design and quality of reporting of randomized controlled trials of chronic idiopathic or autoimmune urticaria: review.

Authors:  Elodie Le Fourn; Bruno Giraudeau; Olivier Chosidow; Marie-Sylvie Doutre; Gérard Lorette
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Effects of omalizumab treatment in patients with refractory chronic urticaria.

Authors:  Young-Hee Nam; Joo-Hee Kim; Hyun Jung Jin; Eui-Kyung Hwang; Yoo-Seob Shin; Young-Min Ye; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2012-04-20       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.